62158-95-6

Basic information

• Product Name: 4-methoxy-N-(2,2,2-trifluoroethyl)aniline
• Synonyms: 4-methoxy-N-(2,2,2-trifluoroethyl)aniline;(4-Methoxyphenyl)(2,2,2-trifluoroethyl)amine
• CAS NO: 62158-95-6
• Molecular Formula: C₉H₁₀F₃NO
• Molecular Weight: 205.178
• Mol File: 62158-95-6.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 236.6 °C at 760 mmHg
• Flash Point: 96.9 °C
• Appearance: /
• Density: 1.237 g/cm³
• CAS DataBase Reference: 4-methoxy-N-(2,2,2-trifluoroethyl)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-methoxy-N-(2,2,2-trifluoroethyl)aniline(62158-95-6)
• EPA Substance Registry System: 4-methoxy-N-(2,2,2-trifluoroethyl)aniline(62158-95-6)

Safety Data

• Hazard Codes: N
• Statements: 51/53
• Safety Statements: 61
• Hazardous Substances Data: 62158-95-6(Hazardous Substances Data)

Usage

General Description

4-methoxy-N-(2,2,2-trifluoroethyl)aniline, also known as MFA, is a chemical compound used in various industries, including pharmaceuticals and agrochemicals. It is a substituted aniline, a type of aromatic amine, with a methoxy group and a trifluoroethyl group attached to the nitrogen atom. MFA is commonly used as an intermediate in the synthesis of organic compounds and as a building block for the production of other chemicals. It has a wide range of applications, including as a reagent in organic chemistry reactions and as a precursor for the synthesis of pharmaceuticals and agrochemicals. MFA is a valuable chemical compound with diverse applications in the chemical industry.

Upstream product

• 104-94-9 4-methoxy-aniline 
• 1547-96-2 2,4,6-tris(2,2,2-trifluoroethoxy)-1,3,5-triazine 
• 373-88-6 2,2,2-trifluroethylamine hydrochloride 
• 753-90-2 trifluoroethylamine 
• 5720-07-0 4-methoxyphenylboronic acid 
• 371-67-5 2,2,2-trifluorodiazoethane 
• 104-92-7 1-bromo-4-methoxy-benzene 
• 623-12-1 4-chloromethoxybenzene 
• 99333-34-3 N-(2,2,2-trifluoroethylidene)-4-methoxyaniline 
• 536-74-3 phenylacetylene 
• 1005385-31-8 N-(2,2,2-trifluoro-1-methoxyethyl)-4-methoxyaniline 
• 332-34-3 2,2,2-trifluoro-N-(4-methoxy-phenyl)-acetamide 
• 75999-66-5 (Z)-2,2,2-trifluoro-N-(4-methoxyphenyl)acetimidoyl chloride 
• 2100-17-6 4-pentenal 

Downstream Products

• 1404508-99-1 N-(4-methoxyphenyl)-N-(2,2,2-trifluoroethyl)ethenesulfonamide 

Relevant articles and documents

Highly enantioselective synthesis of fluorinated γ-amino alcohols through proline-catalyzed cross-Mannich reaction

(Chemical Equation Presented) A new, simple route for the synthesis of fluorinated β-alkyl γ-amino alcohols in optically pure form in only two steps and featuring proline catalysis from inexpensive and readily available starting materials is described. Th

Iron porphyrin-catalyzedN-trifluoroethylation of anilines with 2,2,2-trifluoroethylamine hydrochloride in aqueous solution

An iron porphyrin-catalyzedN-trifluoroethylation of anilines has been developed with 2,2,2-trifluoroethylamine hydrochloride as the fluorine source. This one-pot N-H insertion reaction is conductedviacascade diazotization/N-trifluoroethylation reactions.

Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs)

As the mutant estrogen receptor (ER) continues to be characterized, breast cancer is becoming increasingly difficult to cure when treated with hormone therapy. In this regard, a strategy to selectively and effectively degrade the ER might be an effective alternative to endocrine therapy for breast cancer. In a previous study, we identified a novel series of 7-oxabicyclo[2.2.1]heptene sulfonamide (OBHSA) compounds as full ER antagonists while lacking the prototypical ligand side chain that has been widely used to induce antagonism of ERα. Further crystal structure studies and phenotypic assays revealed that these compounds are selective estrogen receptor degraders (SERDs) with a new mechanism of action. However, from a drug discovery point of view, there still is room to improve the potency of these OBHSA compounds. In this study, we have developed new classes of SERDs that contain the OBHSA core structure and different side chains, e.g., basic side chains, long alkyl acid side chains, and glycerol ether side chains, to simply mimic the degrons of proteolysis targeting chimera (PROTAC) and then investigated the structure-activity relationships of these PROTAC-like hybrid compounds. These novel SERDs could effectively inhibit MCF-7 cell proliferation and demonstrated good ERα degradation efficacy. Among the SERDs, compounds 17d, 17e and 17g containing a basic side chain with a N-trifluoroethyl substituent and a para methoxyl group at the phenyl group of the sulfonamide turned out to be the best candidates for ER degraders. A further docking study of these compounds with ERα elucidates their structure-activity relationships, which provides guidance to design new PROTAC degrons targeting ER for breast cancer therapy. Lastly, easy modification of these PROTAC-like SERDs enables further fine-tuning of their pharmacokinetic properties, including oral availability.